should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous manifestations of psoriatic disease need to be considered in treatment targets.
When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.
Psoriasis (PSO) and psoriatic arthritis (PsA) are debilitating diseases that impact the life quality of ... 1 Injectable biologics (TNF-α, IL-12/IL-23, IL-17 and IL-23 inhibitors) are approved for the ...
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...
Psoriatic arthritis is a form of arthritis that often accompanies psoriasis ... it is important that you work with your doctor and health care providers to come up with a treatment plan that works for ...